Genmab

epkinly-approval-for-dlbcl-treatment

Jun 10, 2025

Abbvie-Genmab’s EPKINLY/TEPKINLY Performance in DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

pharma-news

Jun 11, 2020

AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;

TRAIL-Receptor-Agonists

Feb 17, 2017

TRAIL Receptor Agonists: Emerging target therapies against Cancer

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper